⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

July 15, 2025

Figure 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study

María Alsina Guillermo Villacampa Carlos E. de Andrea Ana Vivancos Mariano Ponz‐Sarvisé Virginia Arrazubi Paula Jiménez‐Fonseca Marc Díez Enrique Sanz‐García Eva Martínez de Castro Raquel Guardeño Mariona Calvo Cristina Bugés Federico Longo Vı́ctor Navarro Eduardo García‐Galea Alena Gros María C. Ochoa Álvaro López‐Janeiro Sandra Sánchez‐Gregorio Claudia Herrero Ibone Labiano María Vila-Casadesús Dario López Raluca Alexandru Susana Muñoz Josep Tabernero Ignacio Melero

View at Publisher

Ask AI

Bookmark

Share

Key Points

MAIN FINDING: Avelumab combined with chemotherapy improves progression-free survival in gastric cancer patients.
KEY EVIDENCE: Results show significant tumor regression grade changes associated with PD-L1, HER2, and MMR status.
APPROACH: Phase II trial involved evaluating efficacy endpoints, including OS and PFS, for resectable cancer.
SIGNIFICANCE: These findings could lead to better treatment strategies for patients with gastric and gastroesophageal junction cancers.

Implication

Phase II trial shows avelumab with chemotherapy improves PFS and OS in gastric cancer, suggesting a new treatment approach.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Alsina et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc6de https://doi.org/10.1158/1078-0432.29568220

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study2025
2Data from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study2025
3Figure 2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study2025
4Table 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study2025
5Supplementary Methodology S1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study2025

More related papers

Figure 3 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study2025
Supplementary Figure S2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study2025
FIGURE 1 from First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study2024